GlassScriptPhysician profile
Mary B Toporcer
NPI 1295738458
$11,689.56
in general payments reported to CMS, 2019-2025
41 companies · $2,506 in 2025
The $2,506 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,179 · 2020: $1,206 · 2021: $1,630 · 2022: $1,672 · 2023: $1,750 · 2024: $1,747 · 2025: $2,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,966 · Education: $36.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,966.31 |
| Education | $36.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,603.90 | 2019-2025 | Tremfya, Stelara, Remicade |
| Abbvie INC. | $1,250.65 | 2019-2025 | Rinvoq, Skyrizi |
| Regeneron Healthcare Solutions, INC. | $1,222.29 | 2019-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $941.67 | 2019-2025 | Adbry, Spevigo, Anzupgo |
| Sun Pharmaceutical Industries INC. | $800.92 | 2019-2025 | Absorica Ld, Winlevi, Ilumya |
| Genzyme Corporation | $599.15 | 2019-2025 | |
| Pfizer INC. | $508.44 | 2019-2025 | |
| Vyne Pharmaceuticals INC. | $488.81 | 2020-2021 | |
| Lilly USA, LLC | $480.09 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $373.28 | 2019-2025 | Bimzelx |
| Incyte Corporation | $354.94 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $335.99 | 2019-2025 | Nemluvio, Epsolay, Dysport |
| Novartis Pharmaceuticals Corporation | $311.96 | 2019-2025 | |
| Genentech USA, INC. | $260.37 | 2019-2023 | Erivedge |
| E.R. Squibb & Sons, L.L.C. | $256.71 | 2024-2025 | Sotyktu |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Toporcer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.